TRβ-Selective Thyromimetics for Neurodegenerative and Fibrotic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for further selective thyromimetic compounds and products containing them, as well as methods for their use and preparation, particularly for treating neurodegenerative disorders such as demyelinating diseases and fibrotic diseases associated with increased TGF-β activity, where existing compounds face challenges due to high sequence homology of thyroid hormone receptor subtypes.
Innovation Solution
Development of compounds according to Formula I, which include specific structural features allowing selective activation of the TRβ receptor, acting as agonists or prodrugs that can be processed in specific tissues, thereby treating neurodegenerative disorders and fibrotic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormone (TH) is used for remyelination therapy, then remyelination is stimulated, but cardiotoxicity and bone demineralization occur due to chronic hyperthyroidism
Solution Approach 1:
The patent applies local quality by creating TRβ-selective agonists that specifically target thyroid hormone receptors in the liver and brain while avoiding TRα receptors in the heart and bone. This selective receptor activation achieves remyelination benefits without the systemic side effects of chronic hyperthyroidism, as the compounds are designed to bind preferentially to TRβ subtypes based on their molecular structure and receptor binding affinity differences.
Solution Approach 2:
The patent segments the thyroid hormone receptor system into distinct TRα and TRβ subtypes with different tissue distributions. By developing compounds that selectively activate only TRβ receptors, the invention separates the therapeutic remyelination function from the harmful effects mediated through TRα receptors, thereby achieving targeted therapy without off-target toxicity.
2Measurement precision
If TRβ-selective agonists are developed, then selectivity between TRα and TRβ is improved, but the high sequence homology of receptor subtypes makes compound development challenging
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of thyroid hormone analogs, including substitution patterns on aromatic rings, linker chain lengths, and functional group configurations. These structural parameter variations are optimized to exploit the single amino acid residue difference between TRα and TRβ binding cavities, achieving high receptor selectivity through precise molecular design rather than complex multi-component systems.
Solution Approach 2:
The patent focuses local quality modifications at the ligand binding domain interface, where the single amino acid difference between TRα and TRβ subtypes creates a distinct molecular recognition environment. By designing compounds with specific local structural features that complement TRβ's unique binding pocket geometry and chemistry, the invention achieves high selectivity without requiring complex overall molecular structures.
3Reliability
If thyromimetic compounds are used to inhibit TGF-β signaling, then fibrotic responses are attenuated, but achieving tissue-specific action without off-target effects is difficult
Solution Approach 1:
The patent applies local quality by designing TRβ-selective agonists that concentrate their pharmacological action in TRβ-expressing tissues such as the liver and brain, where TGF-β-mediated fibrosis is particularly relevant. The selective receptor activation ensures that TGF-β signaling inhibition occurs primarily in these target tissues through localized thyroid hormone pathway modulation, minimizing off-target effects in TRα-dominated organs like the heart and bone.
Data Source
AI summary
Compounds are provided having the structure of Formula (I):or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.